【摘要】 随着我国老龄化的到来,老年性胃癌的发病率不断升高,由于其普遍存在糖尿病、高血压及肝肾功能不全等基础疾病,往往不能耐受手术和放化疗,因此不良反应更小的靶向治疗逐渐成为临床首选。随着分子生物学的发展,人们对胃癌的发生、发展及侵袭机制有了更明确的认识,并在此基础上研制出诸多靶向药物,其中抗表皮生长因子受体(EGFR)靶向药物、抗HER2靶向药物、表皮生长因子络氨酸激酶抑制剂、抗血管生成的靶向药等,均取得了不错的疗效,本文将对此进行综述。更多还原

【Abstract】 With the population aging in China,the incidence of senile gastric cancer is increasing.However,due to the prevalence of diabetes,hypertension,liver and kidney dysfunction and other basic diseases in the elderly,they are often unable to tolerate surgery or chemoradiotherapy,so targeted therapy with fewer adverse reactions gradually become the preferred clinical treatment.With the development of molecular biology,people have a better understanding of the occurrence,development and invasion mechanism of gastric cancer.And many targeted drugs have been developed on this basis which have achieved a good therapeutic effect,including anti-epidermal growth factor receptor(EGFR)targeted drugs,anti-HER2 targeted drugs,epidermal growth factor tyrosine kinase inhibitors,anti-angiogenesis targeted drugs.This article will summarize the above.更多还原